Avutometinib plus defactinib for RAS or BRAF mutated gynecologic cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 trial tests a two-drug treatment (avutometinib plus defactinib) for certain advanced gynecologic cancers that have specific cancer-driving DNA changes (like RAS or BRAF). It’s designed for people whose cancer has returned or gotten worse after at least one prior treatment for metastatic disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older.
- You have a confirmed gynecologic cancer type, such as endometrioid cancer, MOC, HGSOC, or other solid gynecologic cancers.
- Your tumor must have one of these changes: a RAS mutation, a BRAF mutation (types I/II/III), NF-1 loss, and/or RAS activation—confirmed by past tumor genetic testing (or new testing using tissue).
- Your cancer has progressed or come back after at least one prior treatment for metastatic disease, and you have measurable disease on scans.
- You can take pills by mouth and your recent health labs and heart testing must meet the trial’s thresholds.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests a combination of three targeted drugs (avutometinib, defactinib, and everolimus) for people whose endometrial cancer has a specific change in the RAS pathway and has not responded to other treatments. The goal is to see if this drug combo can shrink tumors or slow their growth.
This trial tests a combination of two oral targeted drugs for people with recurrent low-grade serous ovarian cancer. It aims to see if this therapy works better than standard hormone therapy or chemotherapy options.
This trial lets people who are already doing well on a study treatment keep receiving it. It tests whether continuing the combination of avutometinib and defactinib remains safe and helpful for recurrent low-grade serous ovarian cancer.
This trial tests a combination of two oral targeted drugs (avutometinib and defactinib) plus letrozole (a hormone therapy) in people with low-grade serous ovarian cancer who have not yet had any systemic treatment.
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
Hear when a new High Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.